Skip to main content
Journal cover image

Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.

Publication ,  Journal Article
Le, TK; Brown, I; Goldberg, R; Taylor, MT; Deng, J; Parthasarathy, V; Bordeaux, ZA; Alphonse, MP; Kwatra, MM; Naranbhai, V; Gusev, A; Kang, S ...
Published in: J Invest Dermatol
November 2022

Cutaneous immune-related adverse events (cirAEs) are the most prevalent complication to arise from immunotherapy and cause significant morbidity. We aimed to determine the spectrum, timing, clinical features, and outcomes of cirAEs by conducting an observational pharmacovigilance study using VigiBase, the World Health Organization's global database of individual case safety reports from over 130 member countries (ClinicalTrials.gov, number NCT04898751). We compared adverse event reporting in patients who received immune checkpoint inhibitors (91,323 adverse events) with those of the full reporting database (18,919,358 adverse events). There were 10,933 cases of cirAEs within 51 distinct dermatologic types, with 27 specific eruptions with disproportionate signal represented (information component [IC]025 > 0). Of these 27 eruptions, there were eight cirAEs with n > 100 reports, including vitiligo (IC025 = 4.87), bullous pemphigoid (IC025 = 4.08), lichenoid dermatitis (IC025 = 3.69), erythema multiforme (IC025 = 1.03), toxic epidermal necrolysis (IC025 = 0.95), Stevens‒Johnson syndrome (IC025 = 0.41), drug eruption (IC025 = 0.11), and eczematous dermatitis (IC025 = 0.11). There were differences in time to onset after immune checkpoint inhibitor initiation, with a median of approximately 1 month (erythema multiforme, Stevens‒Johnson syndrome, and toxic epidermal necrolysis), 2 months (drug eruption and eczematous dermatitis), 4 months (lichenoid dermatitis), and 5‒6 months (bullous pemphigoid and vitiligo). CirAEs are diverse, dependent on cancer type, and have distinct and different onset times that are linked to the cirAE subtype.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Invest Dermatol

DOI

EISSN

1523-1747

Publication Date

November 2022

Volume

142

Issue

11

Start / End Page

2896 / 2908.e4

Location

United States

Related Subject Headings

  • Vitiligo
  • Stevens-Johnson Syndrome
  • Pharmacovigilance
  • Pemphigoid, Bullous
  • Immune Checkpoint Inhibitors
  • Humans
  • Erythema Multiforme
  • Eczema
  • Drug Eruptions
  • Dermatology & Venereal Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Le, T. K., Brown, I., Goldberg, R., Taylor, M. T., Deng, J., Parthasarathy, V., … Kwatra, S. G. (2022). Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol, 142(11), 2896-2908.e4. https://doi.org/10.1016/j.jid.2022.04.020
Le, Thomas K., Isabelle Brown, Rebecca Goldberg, Matthew T. Taylor, Junwen Deng, Varsha Parthasarathy, Zachary A. Bordeaux, et al. “Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.J Invest Dermatol 142, no. 11 (November 2022): 2896-2908.e4. https://doi.org/10.1016/j.jid.2022.04.020.
Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V, et al. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol. 2022 Nov;142(11):2896-2908.e4.
Le, Thomas K., et al. “Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.J Invest Dermatol, vol. 142, no. 11, Nov. 2022, pp. 2896-2908.e4. Pubmed, doi:10.1016/j.jid.2022.04.020.
Le TK, Brown I, Goldberg R, Taylor MT, Deng J, Parthasarathy V, Bordeaux ZA, Alphonse MP, Kwatra MM, Naranbhai V, Gusev A, Alhariri J, LeBoeuf NR, Reynolds KL, Cappelli LC, Naidoo J, Brahmer JR, Kang S, Semenov YR, Kwatra SG. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. J Invest Dermatol. 2022 Nov;142(11):2896-2908.e4.
Journal cover image

Published In

J Invest Dermatol

DOI

EISSN

1523-1747

Publication Date

November 2022

Volume

142

Issue

11

Start / End Page

2896 / 2908.e4

Location

United States

Related Subject Headings

  • Vitiligo
  • Stevens-Johnson Syndrome
  • Pharmacovigilance
  • Pemphigoid, Bullous
  • Immune Checkpoint Inhibitors
  • Humans
  • Erythema Multiforme
  • Eczema
  • Drug Eruptions
  • Dermatology & Venereal Diseases